Diagnostix, the European medical technology company co-founded by Giuliano Senese and Peter Velthuis, has announced a major partnership with Alfa Romeo F1 Team, one of the leading teams in the world of Formula 1. This exciting collaboration will see Diagnostix's cutting-edge biometric performance analysis hardware integrated with the Alfa Romeo team, providing a new level of insight into the performance and health of drivers.

With a strong commitment to innovation and technology, Diagnostix is dedicated to advancing the field of medical diagnostics and improving the lives of patients everywhere. Now, with their expansion into the world of motorsports, the company aims to use their expertise to enhance the driving experience and provide unique insights into the performance and health of drivers.

Speaking about the partnership, Senese and Velthuis expressed their excitement at the opportunity to work with such a respected and innovative team. "We are thrilled to be partnering with Alfa Romeo Racing Orlen, a team that shares our commitment to innovation and technology," said Senese. "Together, we believe that we can bring a new level of insight and analysis to the world of motorsports, and ultimately improve the performance and safety of drivers."

The partnership between Diagnostix and Alfa Romeo is just the latest example of the growing trend of medical technology companies entering the world of sports. As the technology behind biometric performance analysis continues to evolve and improve, it is becoming an increasingly valuable tool for athletes and teams in a wide range of sports.

For Diagnostix, the partnership with Alfa Romeo represents a major milestone in the company's expansion into new markets. With their cutting-edge technology and commitment to innovation, the company is well positioned to make a major impact in the world of motorsports and beyond.

"We are excited to be working with Alfa Romeo Racing Orlen, and we look forward to bringing our biometric performance analysis hardware to market in collaboration with one of the world's leading Formula 1 teams," said Velthuis. "This partnership represents a major step forward for our company, and we are confident that it will help us to achieve our goal of using technology to improve people's lives."

The company further plans to go public via an IPO relatively soon. It is planning on going public on Nasdaq with ticker DXM.